期刊
BMJ-BRITISH MEDICAL JOURNAL
卷 347, 期 -, 页码 -出版社
BMJ PUBLISHING GROUP
DOI: 10.1136/bmj.f6650
关键词
-
资金
- Medical Research Council, UK
- The Wellcome Trust
- National Institute for Health Research postdoctoral fellowship [PDF-2011-04-007]
- Barts Health Cardiovascular Biomedical Research Unit
- National Institute for Health Research
- UK National Institute for Health Research [RP-PG-0407-10314]
- Wellcome Trust [086091/Z/08/Z]
- MRC
- Arthritis Research UK
- British Heart Foundation
- Cancer Research UK
- Economic and Social Research Council
- Engineering and Physical Sciences Research Council
- National Institute of Health Research
- National Institute for Social Care and Health Research (Welsh Assembly Government)
- Chief Scientist Office (Scottish Government Health Directorates)
- Wellcome Trust
- MRC [G0902135] Funding Source: UKRI
- Medical Research Council [G0902135, MR/K006584/1] Funding Source: researchfish
- National Institute for Health Research [NF-SI-0510-10090, PDF-2011-04-007, NF-SI-0510-10270, RP-PG-0407-10314] Funding Source: researchfish
- National Institutes of Health Research (NIHR) [RP-PG-0407-10314] Funding Source: National Institutes of Health Research (NIHR)
Objectives To investigate whether the use and timing of prescription of beta blockers in patients with chronic obstructive pulmonary disease (COPD) having a first myocardial infarction was associated with survival and to identify factors related to their use. Design Population based cohort study in England. Setting UK national registry of myocardial infarction (Myocardial Ischaemia National Audit Project (MINAP)) linked to the General Practice Research Database (GPRD), 2003-11. Participants Patients with COPD with a first myocardial infarction in 1 January 2003 to 31 December 2008 as recorded in MINAP, who had no previous evidence of myocardial infarction in their GPRD or MINAP record. Data were provided by the Cardiovascular Disease Research using Linked Bespoke studies and Electronic Health Records (CALIBER) group at University College London. Main outcome measure Cox proportional hazards ratio for mortality after myocardial infarction in patients with COPD in those prescribed beta blockers or not, corrected for covariates including age, sex, smoking status, drugs, comorbidities, type of myocardial infarction, and severity of infarct. Results Among 1063 patients with COPD, treatment with beta blockers started during the hospital admission for myocardial infarction was associated with substantial survival benefits (fully adjusted hazard ratio 0.50, 95% confidence interval 0.36 to 0.69; P<0.001; median follow-up time 2.9 years). Patients already taking a beta blocker before their myocardial infarction also had a survival benefit (0.59, 0.44 to 0.79; P<0.001). Similar results were obtained with propensity scores as an alternative method to adjust for differences between those prescribed and not prescribed beta blockers. With follow-up started from date of discharge from hospital, the effect size was slightly attenuated but there was a similar protective effect of treatment with beta blockers started during hospital admission for myocardial infarction (0.64, 0.44 to 0.94; P=0.02). Conclusions The use of beta blockers started either at the time of hospital admission for myocardial infarction or before a myocardial infarction is associated with improved survival after myocardial infarction in patients with COPD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据